Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transaction is subject to regulatory approvals and a customary post-closing purchase price
Subscribe to our email newsletter
Thermo Fisher Scientific has signed an agreement to acquire BRAHMS for approximately $470m. The transaction is expected to be accretive to earnings per share in 2010.
The transaction, which is expected to close in late September 2009, is subject to regulatory approvals and a customary post-closing purchase price adjustment. BRAHMS will be integrated into the Specialty Diagnostics business within Thermo Fisher’s Analytical Technologies Segment.
Marijn Dekkers, president and CEO of Thermo Fisher Scientific, said: “BRAHMS is a significant addition to our specialty diagnostics portfolio, bringing exciting new products and technologies to an area of our company that offers some of our greatest opportunities for growth.
“BRAHMS assays and instrumentation are a strong complement to our existing products for immunoassay testing, and its robust R&D pipeline creates opportunities to commercialise new patented diagnostic tests. In addition, the company gives us a significant reagent manufacturing footprint in Europe, while allowing us to leverage our deep customer access in the US to market new BRAHMS products, such as PCT and others now in development.”